EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Torrent Pharmaceuticals EBITDA Margin % Related Terms
Torrent Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:TORNTPHARM vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Torrent Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Torrent Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a EBITDA Margin % of 30.84% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Torrent Pharmaceuticals and its competitors. This is near median its historical median of 29.94. Over the past decade, Torrent Pharmaceuticals' EBITDA Margin % has ranged from 22.52 to 33.14. According to the industry distribution chart, Torrent Pharmaceuticals ranks #107 out of 952 companies in the Drug Manufacturers industry, placing it in the top 11.2%.
Is Torrent Pharmaceuticals' EBITDA Margin % too high?
Torrent Pharmaceuticals' current EBITDA Margin % of 30.84% is near median its 10-year median of 29.94. Over the past 10 years, this metric has ranged from a low of 22.52 to a high of 33.14. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Torrent Pharmaceuticals' value of 30.84% is 147.3% above this industry median. Based on the distribution chart, Torrent Pharmaceuticals ranks #107 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Torrent Pharmaceuticals has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Torrent Pharmaceuticals ranks #107 out of 952 companies for EBITDA Margin %. This places Torrent Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Torrent Pharmaceuticals' value of 30.84% is 147.3% above this benchmark. Historically, Torrent Pharmaceuticals' own EBITDA Margin % has ranged from 22.52 to 33.14 over the past decade. While the company's 10-year median is 29.94 vs. the industry median of 12.47, Torrent Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Torrent Pharmaceuticals's current EBITDA Margin % of 30.84% is 147.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Torrent Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Torrent Pharmaceuticals's current EBITDA Margin % is 30.84%, which is near median its own 10-year median of 29.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,296.81, compared to a current price of ₹4,516.20 — trading 5.1% above its estimated fair value. The current EBITDA Margin % is 30.84%, which is near median its 10-year median of 29.94 and 147.3% above the Drug Manufacturers industry median of 12.47. Torrent Pharmaceuticals' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current EBITDA Margin % is 30.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹4,516.20 is trading 5.1% above its estimated GF Value™ of ₹4,296.81.
GuruFocus considers Torrent Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:TORNTPHARM:
EBITDA Margin %: 30.84% (near median its 10-year median of 29.94)
GF Value™: ₹4,296.81 vs. price of ₹4,516.20 (5.1% above fair value)
Industry Position: 147.3% above the Drug Manufacturers median (#107 of 952)
No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
80GF Score
Get the complete analysis for NSE:TORNTPHARM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TORNTPHARM has been successfully added to your 
